ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors ...
NDAQ:SPRY) ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm ...
News4Jax1 天
More nasal spray medications: Are vaccines next?
Whether it’s allergies, a sinus infection or runny nose, many people turn to nasal sprays for quick relief. Now, there’s ...
ARS Pharmaceuticals更新制造协议条款
加利福尼亚州圣地亚哥 - 根据最近向美国证券交易委员会提交的8-K文件，专门从事药物制剂的制药公司ARS Pharmaceuticals, Inc.已修订了与Renaissance Lakewood, LLC的制造协议。该修订于周一生效，修改了原本于2020年9月9日签订并于2023年7月25日修订的协议条款。
bovnews2 天
ARS Pharmaceuticals Inc (SPRY) Stock’s 1.69% Increase This Year: What’s the Story?
ARS Pharmaceuticals Inc (SPRY) stock saw a decline, ending the day at $14.77 which represents a decrease of $-0.09 or -0.61% from the prior close of $14.86. The stock opened at $14.97 and touched a ...
美国现已推出治疗严重过敏的鼻喷剂
圣地亚哥 - 生物制药公司ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)宣布,其处方药neffy®(肾上腺素鼻喷剂)现已在全美上市。美国食品药品监督管理局(FDA)上月批准了用于治疗体重超过30公斤(66磅)个体I型过敏反应(包括过敏性休克)的2毫克neffy。 通过neffyConnect项目和与在线药房BlinkRx的合作,符合条件的商业保险患者可以25美元的 ...
Monthly Prescribing Reference2 天
Epinephrine Nasal Spray Neffy Now Available to Treat Severe Allergic Reactions
Credit: ARS Pharmaceuticals. Neffy is indicated for adult and pediatric patients weighing at least 30kg. It is recommended that patients be prescribed and have immediate access to 2 neffy nasal sprays ...
yourerie2 天
Health Report: Researching new vaccines to give nasally
Whether it’s allergies, a sinus infection or runny nose many people turn to nasal sprays for quick relief. And now, there’s ...
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ARS Pharmaceuticals ...
NDAQ:SPRY) The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc's Securities Law Violations ...
Singularity Hub4 天
This Week’s Awesome Tech Stories From Around the Web (Through September 21)
From a $100 billion AI investment to a cancer vaccine trial, check out this week's awesome tech stories from around the web.
同花顺股票频道5 天
Leerink Partners：维持ARS Pharmaceuticals(SPRY.US)评级
Leerink Partners：维持ARS Pharmaceuticals(SPRY.US)评级，由优于大市调整至优于大市评级,目标价由21.00美元调整至25.00美元。 ARS Pharmaceuticals(SPRY.US)公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗I型过敏反应(包括过敏反应)的新型、潜在一流 ...
Rocket Report: Eutelsat’s surprising decision; Europe complains about SpaceX again
Iran launches Qaem-100 rocket again. After an initial failure in 2023, Iran has now successfully launched the small, solid ...
同花顺股票频道5 天
美股内部交易 | ARS Pharmaceuticals于9月19日披露6笔公司内部人交易情况
2024年9月19日， ARS Pharmaceuticals（SPRY）披露6笔公司内部人交易情况。持股10%以上股东Lowenthal Richard E于2024年9月18日卖出5.00万股。 2024年9月19日 高管 Karas Eric 2024年9月18日 买入 1.00万 1.50 1.50万 2024年9月19日 持股10%以上股东 Tanimoto Sarina ...